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To the Editor: Mycobacterium 
haemophilum is an aerobic, slow-
growing microorganism with optimal 
growth at 30°C to 32°C. It has a unique 
requirement for ferric iron–containing 
compounds (1), from which it acquired 
its name (i.e., haemophilum). Infec-
tions with M. haemophilum are rare, 
but cervicofacial lymphadenitis caused 
by M. haemophilum has been described 
in children (2). Besides cervicofacial 
lymphadenitis, extrapulmonary signs of 
M. haemophilum disease include sub-
cutaneous noduli, arthritis, and osteo-
myelitis, which generally affect immu-
nocompromised patients (3). Recently, 
2 cases of cutaneous M. haemophilum 
infections after alemtuzumab treatment 
were reported (4). A small number of 
pulmonary M. haemophilum infections 
associated with AIDS or solid organ or 
bone marrow transplantation have been 
described (1). We report pulmonary 
M. haemophilum infection in a wom-
an who had been immunosuppressed 
by tumor necrosis factor-α antagonist 
(TNF-αA) (adalimumab) treatment for 
rheumatoid arthritis.
A 72-year-old woman with a his-
tory of rheumatoid arthritis and ob-
structive sleep apnea syndrome had 
signs and symptoms of fatigue, mild 
fever episodes, and a nonproductive 
cough 9 months after treatment for 
rheumatoid arthritis had begun with 
methotrexate (MTX) and TNF-αA. 
Physical examination was unremark-
able except for a body temperature of 
38.9°C. Laboratory testing showed an 
increased erythrocyte sedimentation 
rate (ESR) (77 mm/h), an increased C-
reactive protein (CRP) level (60 mg/L), 
a normal leukocyte count (8,500 cells/
μL), and relative monocytosis (12%). 
HIV serologic testing results were 
negative. Chest radiograph showed an 
infiltrate in the right upper lobe. Chest 
computed tomography confirmed this 
finding and showed lymphadenopathy 
in the right hilus and mediastinum.
Notably, the tuberculin skin test 
result was negative at screening be-
fore she began the TNF-αA treatment, 
but was now positive (20 mm), sug-
gesting mycobacterial infection. Au-
ramine and Ziehl-Neelsen staining of 
sputum and bronchoalveolar liquids 
showed no acid-fast bacilli, and M. 
tuberculosis infection was not con-
firmed by PCR or culture. Eventu-
ally, a mediastinal lymph node biopsy 
was taken by endoscopic ultrasound 
guidance. Granulomatous inflamma-
tion and acid-fast bacilli were seen 
by microscopy. Corresponding cul-
tures yielded a strain identified as M. 
haemophilum at the Netherlands Na-
tional Institute for Public Health and 
the Environment (RIVM) by using the 
Inno-LiPA Mycobacteria v2 reverse 
line blot assay (Innogenetics, Ghent, 
Belgium). Strain identity was con-
firmed by sequencing of the complete 
16S rDNA gene, which was identical 
to that of M. haemophilum available 
in the GenBank sequence database 
(National Center for Biotechnology 
Information; www.ncbi.nlm.nih.gov; 
accession no. X88923).
The RIVM performed drug sus-
ceptibility testing by using a modi-
fied agar dilution method (5). Mid-
dlebrook 7H10 media were enriched 
with 10% sheep blood hemolyzed 
by 1:1 dilution with water and sub-
sequent freezing–thawing. Historic 
drug susceptibility data was reviewed 
(Table). Initially, adalimumab was 
discontinued, and our patient was 
treated with isoniazid, ethambutol, ri-
fampin, and pyrazinimide because M. 
tuberculosis infection was suspected. 
After identification of M. haemo-
philum, our patient was treated with 
rifampin and azithromycin. A total 
treatment duration of 10 months re-
sulted in complete resolution of the 
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Table. Antimicrobial drug susceptibility test results for Mycobacterium haemophilum
isolate from rheumatoid arthritis patient and other M. haemophilum isolates* 
Case report RIVM historic data (n = 49) Antimicrobial
drug Classification MIC, mg/L % Susceptible % Resistant 
Isoniazid Resistant 10 0 100
Rifampin Susceptible 0.2 4 96
Ethambutol Resistant 20 0 100
Streptomycin Susceptible <1.0 35 65
Cycloserine Susceptible 50 78 22
Prothionamide Susceptible <1.0 61 39
Amikacin Resistant 10 29 71
Ciprofloxacin Resistant 4.0 88 12
Clofazimine Susceptible <0.5 92 8
Clarithromycin Susceptible <2.0 94 6
Rifabutin Susceptible <0.2 96 4
*All isolates submitted to the Mycobacteria Reference Laboratory, National Institute for Public Health 
and the Environment (RIVM), the Netherlands, January 2000–January 2007. Before January 2004, 
strains tested were identified by 16S rDNA gene sequencing; after January 2004, strains were 
identified by the Inno-LiPA assay (Innogenetics, Ghent, Belgium). 
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pulmonary infiltrate and normaliza-
tion of ESR and CRP concentration. 
During the follow- up period of >12 
months, the patient remained asymp-
tomatic. Her rheumatoid arthritis was 
treated with MTX monotherapy.
This case illustrates the risk for 
infectious diseases during TNF-αA 
treatment. Rheumatoid arthritis can 
be treated effectively with MTX and 
TNF-αA (6). Side effects of con-
cern are infectious diseases, which 
prompt the need for screening for la-
tent mycobacterial infection before 
commencing treatment (7). Despite 
screening, mycobacterial infections 
have been diagnosed after prolonged 
treatment in various patients (8). This 
case shows that not only M. tubercu-
losis but also nontuberculous myco-
bacteria (NTM) should be considered 
as possible pathogens. This possibility 
is of clinical importance because of 
the diagnostic challenges. Diagnosing 
NTM infections may require specific 
culture media and molecular assays. 
Under optimal conditions, cultures 
show growth of most NTM species 
(including M.  haemophilum) within 
2–3 weeks. NTM are less susceptible 
to antimicrobial drugs than M. tuber-
culosis. M.  haemophilum is generally 
resistant in vitro to isoniazid, etham-
butol, and rifampicin (Table), but no 
standardized susceptibility methods 
for M. haemophilum exist. Therefore, 
following current guidelines from the 
American Thoracic Society (ATS) is 
advisable for NTM infections (9).
No specific recommendations ex-
ist for pulmonary M. haemophilum 
infections, but for disseminated M. 
haemophilum infections, the ATS rec-
ommends a multidrug regimen com-
bining clarithromycin, rifampicin/
rifabutin, and ciprofloxacin. Although 
no studies on treatment duration for 
M. haemophilum infections have been 
conducted, the ATS guidelines recom-
mend treatment until cultures taken 
during therapy are negative for 1 year 
(9). Whether TNF-αA treatment can 
be continued during antimycobacterial 
treatment is a matter of debate in the 
absence of sufficient safety data (8). 
In active tuberculosis infection, treat-
ment with TNF-αA is contraindicated 
before patients complete a standard 
regimen of antituberculosis therapy; 
no information is available for NTM 
disease (10).
This case is presented especially 
to demonstrate the diagnostic chal-
lenges of NTM infections. For such 
cases, clinicians are advised to consult 
experts in the field of NTM infections.
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